What is in the sample brief?

A complete oncology competitive brief on a public asset: what happened, the number that matters, why it matters, who is exposed, a dated watch list, the strategic options, and every source numbered and linked. Roughly 1,500 words — the same structure and sourcing standard as a client deliverable.

Do I have to give an email to read it?

One work email, and the PDF opens immediately — no name, no company, no phone number, and no sales sequence afterwards. If you would rather not, email hello@prognyx.com and it will be sent to you directly.

Is the free brief on my own asset really free?

Yes, and with no obligation in either direction. It exists because reading the work is a far better way to evaluate a research provider than a call, and because if the brief is not useful there is nothing further to discuss anyway.

How long does a brief on my asset take?

Usually a few days. If the competitive set is large or the primary record is unusually thin, you will be told that up front rather than sent a thinner brief without explanation.

See a Sample Oncology Competitive Brief (PDF)

This is the same document a client receives — same structure, same sourcing rule, same audit — written on a public asset instead of yours. It is roughly 1,500 words, and every factual claim in it links to the primary record it came from.

Download the brief

One work email and the PDF opens immediately. No sales sequence, no qualification call — you get the brief and, if you want it, the briefings as they publish.

One address, one email. Never sold — see privacy. Would rather leave nothing? Email me and I'll send it over.

What is inside a Prognyx brief

What happened. The event, with the date and the document. No preamble.
The number that matters — including, when relevant, the number a company has not disclosed. That absence is often the whole story.
Why it matters. The mechanism of the threat or the opening, in terms of your positioning rather than the news cycle.
Who is exposed, who gained. Named companies and programmes, with the exposure quantified wherever public data allows.
What to watch, with dates. The calendar: readouts, PDUFA goal dates, congress slots. This is what keeps the brief useful a month later.
The now-what. The two or three moves actually on the table for you, stated as options rather than as a recommendation you did not ask for.
Sources. Every one, numbered and linked. You can rebuild the whole analysis yourself.

What to look for while reading it

Three things distinguish a brief that is worth paying for from a well-formatted news summary. Check for them:

Does it say what it doesn't know? Look for the phrase "cannot be confirmed from public sources". A brief that never admits a gap is either lucky or filling.
Do the links go to primary documents? A ClinicalTrials.gov record, an SEC exhibit, an FDA action — not to another article about them.
Is there a decision in it? If the last section is a summary rather than options with dates attached, the analysis stopped one step short of being useful.

Those are also the three tests Prognyx applies to its own output before publishing. The procedure is written up on how we work.

Then get one on your own asset — free

The sample is on a public asset, which means it demonstrates the method but not the fit. The next step is a brief on your competitive set: name one asset you would want watched and you get a real brief on it at no cost, with no obligation and no sales call attached. If it is not the clearest read you have had on your space, that is the end of it and you owe nothing.

Every briefing Prognyx publishes openly is also on The Watchtower — five of them at the time of writing, added to as the field moves. Read those too; they are not curated for the pitch.

Read the actual deliverable first.